Keywords:
Benzathine Penicillin G; COM-B model; Rheumatic heart disease; Theoretical framework of acceptability
Abstract:
Monthly intramuscular injections of benzathine penicillin G (BPG) remain the cornerstone of secondary prophylaxis for acute rheumatic fever and rheumatic heart disease (RHD). The barriers to successful delivery of BPG may be patient- or service-delivery-dependent.